Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow-up.
Nanni, L., Morigi, A., Casadei, B., Broccoli, A., Stefoni, V., Argnani, L., et al. (2019). A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies. HEMATOLOGICAL ONCOLOGY, 37(2), 202-204 [10.1002/hon.2573].
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies
Nanni, Laura;Morigi, Alice;Casadei, Beatrice;Broccoli, Alessandro;Stefoni, Vittorio;Argnani, Lisa;Cavo, Michele;Zinzani, Pier Luigi
2019
Abstract
Existing therapies for Sézary syndrome (SS) are limited in efficacy and in disease control, and patients have very poor prognosis. Here, we report a case report of a patient who has a 16-year history of SS and related treatments (both standard and experimental). In particular, two drugs, one conventional (gemcitabine) and one experimental (mogamulizumab), were able to induce long lasting response. Patient refused to undergo allogeneic stem cell transplantation. After eleven lines of therapeutic approaches, the patient is in very good partial response and free of therapy at the latest available follow-up.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
